COVID-19 Pandemic Delays FDA Review of Vaping Products
A review of vaping products has been delayed by the COVID-19 outbreak.
A review of vaping products has been delayed by the COVID-19 outbreak.
Active cigarette smokers and individuals with COPD could be at increased risk for severe COVID-19.
The prevalence rates of smoking and cessation in adulthood are associated with levels of childhood smoking intensity.
Many articles and studies supporting the therapeutic use of cannabidiol (CBD) have disclosed funding from CBD-related parties.
Legally dispensed marijuana products have stronger concentrations of THC and CBD than needed for chronic pain relief.
Investigators assessed the efficacy and safety of 2 daily doses of cannabidiol, 10 mg/kg or 20 mg/kg, in children with Dravet syndrome.
Diagnoses and symptoms of anxiety, depression, and trauma are associated with cannabis use in pregnant women.
Young adults report ever use of Juul more often than smoking cigarettes and using non-pod-based electronic cigarettes.
Women with depression are more than three times more likely to use cannabis during pregnancy compared with women without depression.
A journal’s retraction of a study linking electronic cigarettes with an increased risk for heart attack is being challenged by the author.